%0 Journal Article
%T Abnormal expression of oxylipins and related synthesizing/signaling pathways in inflammatory bowel diseases.
%A Ben-Mustapha Y
%A Rekik R
%A Ben-Fradj MK
%A Serghini M
%A Sanhaji H
%A Ben-Ahmed M
%A Boubaker J
%A Feki M
%J Prostaglandins Leukot Essent Fatty Acids
%V 202
%N 0
%D 2024 Jul 1
%M 38991597
%F 3.015
%R 10.1016/j.plefa.2024.102628
%X We investigated selected oxylipins and related synthesizing/signaling pathways in 28 patients with Crohn's disease (CD), 19 patients with ulcerative colitis (UC), and 39 controls. Plasma and mucosal PUFA/oxylipin profiles were analyzed by LC-MS/MS. mRNA expression of 5, 12 and 15-lipooxygenases, FPR2/ALXR, FFAR4/GPR120, annexin A1, and interleukin-10 were analyzed by qRT-PCR. Oxylipin profile and related metabolic pathways were altered in both CD and UC patients. The patterns were characterized by increased prostaglandins, leukotrienes, and lipoxins and overexpression of 5-lipoxygenase, FPR2/ALXR, annexin A1, and interleukin-10 genes, but decreased n-3 PUFAs and 18-hydroxyeisapentaenoic acid. The gene of 15-lipoxygenase was under-expressed mainly in UC patients. CD and UC are associated with unbalanced n-6 ​​and n-3 derivatives and pro-inflammatory and anti-inflammatory/pro-resolving mediators favoring the former compounds. The findings suggest that oxylipins engage in the pathophysiology of the diseases. Targeting oxylipin's metabolic pathways would be a promising therapy for inflammatory bowel diseases.